Funds › Tang Capital Management LLC
Tang Capital Management LLC
13F for Q2 2026, filed Aug 14, 2026. 40 positions worth $2.2B.Managers with more than $100 million in US-listed stocks list their holdings each quarter, within 45 days of quarter end. Long positions only: no short sales or cash.
Ask your AI about this
Connect Claude, ChatGPT, Gemini or Grok (Microsoft 365 Copilot coming soon) to 13F.ai and ask in plain English. Copy a question to get started:
Using 13F.ai, what are the biggest new, added, trimmed and exited positions of Tang Capital Management LLC in the latest 13F quarter?
Using 13F.ai, how has Tang Capital Management LLC's portfolio concentration changed over the last four quarters?
Using 13F.ai, which of Tang Capital Management LLC's top holdings have also been bought by insiders recently?
Connect your AI · Plans and the 7-day free trial (card required)
Holdings, Q2 2026
Largest first. Common shares only.
| # | The fund's own figures at the end of the quarter. A report can be up to 45 days old when it is filed. Options and bonds are not counted here. | Filing | ||||
|---|---|---|---|---|---|---|
| 1 | AUPH Aurinia Pharmaceuticals Inc | 13.04M | $221.4M | 10.1% | +6.7% | 13F ↗ |
| 2 | SYRE Spyre Therapeutics, Inc. | 1.89M | $168.0M | 7.6% | Unchanged | 13F ↗ |
| 3 | MIRM Mirum Pharmaceuticals, Inc. | 1.24M | $144.7M | 6.6% | Unchanged | 13F ↗ |
| 4 | KNSA Kiniksa Pharmaceuticals International, plc | 2.26M | $144.5M | 6.6% | Unchanged | 13F ↗ |
| 5 | CELC Celcuity Inc. | 1.31M | $137.5M | 6.2% | +25.2% | 13F ↗ |
| 6 | CORT Corcept Therapeutics Incorporated | 1.50M | $130.4M | 5.9% | Unchanged | 13F ↗ |
| 7 | PTCT PTC Therapeutics, Inc. | 1.50M | $122.4M | 5.6% | Unchanged | 13F ↗ |
| 8 | LKFT Lakefront Biotherapeutics · ADR | 3.79M | $113.5M | 5.2% | Unchanged | 13F ↗ |
| 9 | CAPR Capricor Therapeutics, Inc. | 4.10M | $98.7M | 4.5% | +20.6% | 13F ↗ |
| 10 | TARS Tarsus Pharmaceuticals, Inc. | 1.57M | $98.7M | 4.5% | +31.9% | 13F ↗ |
| 11 | SPY State Street SPDR S&P 500 ETF Trust · Trust units | 123,000 | $91.9M | 4.2% | -26.8% | 13F ↗ |
| 12 | ANAB AnaptysBio, Inc. | 1.33M | $89.8M | 4.1% | -33.3% | 13F ↗ |
| 13 | IMCR Immunocore Holdings plc · ADR | 2.65M | $84.1M | 3.8% | Unchanged | 13F ↗ |
| 14 | CMPS COMPASS Pathways Plc · ADR | 5.00M | $70.8M | 3.2% | +24.9% | 13F ↗ |
| 15 | ANIP ANI Pharmaceuticals, Inc. | 707,500 | $58.6M | 2.7% | Unchanged | 13F ↗ |
| 16 | BNTX BioNTech SE · ADR | 470,000 | $43.7M | 2.0% | Unchanged | 13F ↗ |
| 17 | CMPX Compass Therapeutics, Inc. | 17.99M | $39.4M | 1.8% | +7.1% | 13F ↗ |
| 18 | PGEN Precigen, Inc. | 6.42M | $36.6M | 1.7% | Unchanged | 13F ↗ |
| 19 | VRDN Viridian Therapeutics, Inc. | 1.79M | $32.9M | 1.5% | Unchanged | 13F ↗ |
| 20 | NVCT Nuvectis Pharma, Inc. | 1.55M | $28.5M | 1.3% | New | 13F ↗ |
| 21 | DNTH Dianthus Therapeutics, Inc. | 264,692 | $25.8M | 1.2% | Unchanged | 13F ↗ |
| 22 | FULC Fulcrum Therapeutics, Inc. | 6.52M | $23.9M | 1.1% | New | 13F ↗ |
| 23 | AVIR Atea Pharmaceuticals, Inc. | 4.81M | $22.4M | 1.0% | Unchanged | 13F ↗ |
| 24 | CBIO Crescent Biopharma, Inc. | 1.16M | $20.9M | 0.9% | Unchanged | 13F ↗ |
| 25 | NNDM Nano Dimension Ltd. · ADR | 14.29M | $20.7M | 0.9% | New | 13F ↗ |
| 26 | VKTX Viking Therapeutics, Inc. | 500,000 | $19.5M | 0.9% | Unchanged | 13F ↗ |
| 27 | NUVB Nuvation Bio Inc. | 3.30M | $18.7M | 0.9% | +4.8% | 13F ↗ |
| 28 | IDYA IDEAYA Biosciences, Inc. | 450,000 | $16.8M | 0.8% | Unchanged | 13F ↗ |
| 29 | DERM Journey Medical Corporation | 1.61M | $11.4M | 0.5% | Unchanged | 13F ↗ |
| 30 | INSM Insmed Incorporated · Com Par $.01 | 100,000 | $10.7M | 0.5% | -61.5% | 13F ↗ |
| 31 | STOK Stoke Therapeutics, Inc. | 300,000 | $9.8M | 0.4% | -40.0% | 13F ↗ |
| 32 | PLRX Pliant Therapeutics, Inc. | 6.14M | $7.0M | 0.3% | Unchanged | 13F ↗ |
| 33 | BOLD Boundless Bio, Inc. | 2.56M | $6.4M | 0.3% | New | 13F ↗ |
| 34 | PMVP PMV Pharmaceuticals, Inc. | 4.25M | $5.7M | 0.3% | Unchanged | 13F ↗ |
| 35 | MRNA Moderna, Inc. | 50,000 | $3.5M | 0.2% | -50.0% | 13F ↗ |
| 36 | Wave Life Sciences Ltd | 600,000 | $3.5M | 0.2% | Unchanged | 13F ↗ |
| 37 | HRTX Heron Therapeutics, Inc. | 6.25M | $2.7M | 0.1% | Unchanged | 13F ↗ |
| 38 | LENZ LENZ Therapeutics, Inc. | 451,114 | $2.6M | 0.1% | Unchanged | 13F ↗ |
| 39 | ALT Altimmune, Inc. | 666,022 | $2.0M | 0.1% | Unchanged | 13F ↗ |
| 40 | RCKT Rocket Pharmaceuticals, Inc. | 100,000 | $342.0K | <0.1% | Unchanged | 13F ↗ |
Changes since Q1 2026
4 new, 7 added to, 6 trimmed, 15 exited, 23 unchanged. By estimated dollars.
New positions (4)
Added to (7)
| CELC Celcuity Inc. | 1.31M | +25.2% | $27.7M |
| TARS Tarsus Pharmaceuticals, Inc. | 1.57M | +31.9% | $23.9M |
| CAPR Capricor Therapeutics, Inc. | 4.10M | +20.6% | $16.9M |
| CMPS COMPASS Pathways Plc · ADR | 5.00M | +24.9% | $14.1M |
| AUPH Aurinia Pharmaceuticals Inc | 13.04M | +6.7% | $13.8M |
| CMPX Compass Therapeutics, Inc. | 17.99M | +7.1% | $2.6M |
| NUVB Nuvation Bio Inc. | 3.30M | +4.8% | $852.0K |
Trimmed (6)
| ANAB AnaptysBio, Inc. | 1.33M | -33.3% | -$44.9M |
| SPY State Street SPDR S&P 500 ETF Trust · Trust units | 123,000 | -26.8% | -$33.6M |
| INSM Insmed Incorporated · Com Par $.01 | 100,000 | -61.5% | -$17.1M |
| STOK Stoke Therapeutics, Inc. | 300,000 | -40.0% | -$6.5M |
| MRNA Moderna, Inc. | 50,000 | -50.0% | -$3.5M |
| PLRX Pliant Therapeutics, Inc. | 6.14M | Unchanged | -$2,133 |
Exited (15)
| Kalvista Pharmaceuticals Inc | 4.57M | Exited | -$92.1M |
| JANX Janux Therapeutics, Inc. | 500,000 | Exited | -$7.0M |
| BIIB Biogen Inc. | 35,000 | Exited | -$6.4M |
| URGN UroGen Pharma Ltd. | 350,000 | Exited | -$6.3M |
| ARVN Arvinas, Inc. | 538,658 | Exited | -$5.7M |
| Kezar Life Sciences Inc | 664,314 | Exited | -$4.9M |
| AGIO Agios Pharmaceuticals, Inc. | 100,000 | Exited | -$3.4M |
| ERAS Erasca, Inc. | 200,000 | Exited | -$3.2M |
| CHRS Coherus Oncology, Inc. | 1.89M | Exited | -$3.2M |
| NKTX Nkarta, Inc. | 1.48M | Exited | -$3.1M |
The 10 largest of each, by estimated dollars: shares changed times the later report's price. Index tracking, splits and mergers move positions too.
Compare two quarters
Pick any two quarters: what is new, added to, trimmed or exited. Premium plan.
Reported value by quarter
Value and number of positions at the end of each quarter.
Loading…
Largest positions in earlier quarters
Pick a quarter to see what the fund's biggest positions were then.
Loading…
Ten largest positions
By value, Q2 2026.
Filings
Most recent first, up to 80. An amendment can replace a report or add holdings to it. All 13F filings
Information, not investment advice. Values are the fund's own figures at quarter end; a report can be up to 45 days old when filed. Disclaimer